Nanohsa-Rotop (Human Serum Albumin)

Human Serum Albumin increases the colloid osmotic pressure within the bloodstream. By providing exogenous albumin, it draws fluid from the interstitial space into the vascular compartment, expanding plasma volume and improving circulatory function in patients with fluid deficits or low albumin levels.

The prescribed dose of Nanohsa‑Rotop is individualized by the treating clinician based on the patient’s clinical status, degree of volume loss, albumin concentration, and target hemodynamic goals. No fixed regimen is provided; dosing decisions are made at the point of care.

Safety data for Nanohsa‑Rotop during pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the prescribing physician.

To order Nanohsa‑Rotop, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Nanohsa‑Rotop provides a natural colloid solution, offering higher oncotic pressure than crystalloids such as saline and fewer renal side effects than some synthetic colloids. Compared with synthetic options, albumin carries a lower risk of coagulopathy but is more expensive and requires cold‑chain handling.

Nanohsa‑Rotop must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product to maintain stability and sterility.

Nanohsa‑Rotop is administered by intravenous or subcutaneous infusion under aseptic conditions. The infusion rate is determined by the clinician, and the solution should be given through a suitable filter to ensure particle removal before administration.

The most serious adverse events include anaphylactic reactions, pulmonary edema due to fluid overload, and severe hypertension. Immediate medical attention is required if any signs of these reactions appear during or after infusion.

Nanohsa‑Rotop is contraindicated in patients with known hypersensitivity to human serum albumin, severe uncontrolled heart failure, or uncontrolled hypertension. Caution is also advised for individuals with renal impairment or those at high risk of fluid overload.